Citations

Clear

949 citation(s) found for "Li, Bryan".

Abstract WP61: Automated Retinal Vascular Fractal Analysis Can Screen Presymptomatic Alzheimer’s Disease
Nikolova, Jennifer, Woodruff, Bryan K. , Dumitrascu, Oana M.

Mayo Clinic

Stroke | January 30, 2025 | Volume: 56 | Issue: Suppl_1 | Pages: No page available

10.1161/str.56.suppl_1.wp61 Get It

Background: Retinal vasculopathy had been reported across the continuum of neurodegeneration. Retinal color fundus photography coupled with automated retinal vascular analysis offers potential to non-invazively screen for Alzheimer’s disease (AD) neurodegeneration. Amyloid positron emission tomography (PET) and apolipoprotein 4 (APOE4) carrier status are known biomarkers of AD risk. Herein, we examined the relationship between retinal vascular fractal dimensions in non-mydriatic color fundus photographs, amyloid-PET burden and APOE4 carrier status in a cohort of cognitively intact individuals. Methods: Our dataset included 91 macula-centered and 39 optic disc-centered images from 96 cognitively intact participants (29% male). 25 (26%) were amyloid-PET positive, defined as amyloid-PET standardized uptake value ratio centiloid cut-off > 20. AutoMorph software automatically determined retinal arteriolar and venular density, tortuosity and width, among other fractal dimensions. To test the effect of amyloid-PET status on the retinal vascular parameters, we used a generalized linear model compensated for age, sex and the interaction between APOE4 carrier and amyloid-PET status. We also compared amyloid-PET positive and negative subjects for vascular fractal dimensions correcting for age and gender. We adjusted for multiple comparisons using the False Discovery Rate correction and reported significant P values less than 0.05. Results: Compared to amyloid-PET negative, cognitively intact amyloid-PET positive cohort had greater mean age (71 vs 66 years, P=0.06), more males (60% vs 35%, P=0.02), more APOE4 carriers (P<0.001), similar vascular risk factors (hypertension, dyslipidemia, diabetes mellitus, smoking, P>0.05 for all) and significantly lower macular vessel tortuosity density (P=0.019). The amyloid-PET positive status had a significant effect on the retinal artery distance tortuosity (corrected P=8.75E-04, β=13.9, 95% CI [7.75-19.99]) and artery squared curvature tortuosity (corrected P=8.91E-10, β=464, 95% CI [359.10-569.15]). Conclusions: Automatically determined retinal vascular fractal dimension on non-mydriatic color fundus photographs predicts amyloid-PET burden in cognitively intact individuals. Future longitudinal studies should asssess the utility of automated quantitative retinal vasculopathy analysis to screen for presymptomatic AD.
Schlemm’s Bidirectional Fluid Wave and Luminal Blood Reflux as Novel Intraoperative Signs Confirming Optimal Placement of the iStent
Ang, Bryan Chin Hou , Lim, Sheng Yang , Ang, Bryan C H , Betzler, Bjorn Kaijun

Mayo Clinic

Journal of Glaucoma | January 22, 2025 | Volume: 34 | Issue: 6 | Pages: e28-e33

10.1097/ijg.0000000000002539 | PMID 39841095 Get It

Purpose: Trabecular micro-bypass devices (TBDs) such as the iStent series (Glaukos Corporation), are effective in reducing intraocular pressure (IOP). However, precise placement of TBDs is crucial in achieving surgical efficacy, as device malpositioning may lead to suboptimal IOP reduction. We demonstrate 2 novel intraoperative signs to aid confirmation of accurate iStent placement, without reliance on imaging technologies. Methods: Surgical technique report with video accompaniment. Surgical Technique: Two intraoperative clinical signs that confirm optimal iStent placement are described: (1) Luminal Blood Reflux—achieved by gently decompressing the anterior chamber, with or without flushing of the stent lumen with balanced salt solution (BSS), thereby confirming stent positioning in the Schlemm canal (SC). (2) Schlemm’s Bidirectional Fluid Wave (SBFW)—observable when flushing with BSS, suggesting fluid movement in the canal segments adjacent to the iStent device, thereby confirming stent patency and positioning in the SC. Conclusion: The identified signs are useful, feasible, and reproducible indicators of accurate iStent placement. Future studies may evaluate the application of these confirmatory maneuvers in diverse clinical contexts and further establish a correlation with clinical outcomes.
Parameterization of intraoperative human microelectrode recordings: Linking action potential morphology to brain anatomy
Baker, Matthew , Klassen, Bryan T. , Jensen, Michael A. , Valencia, Gabriela Ojeda , Heydari, Hossein, Ince, Nuri F. , Müller, Klaus‐Robert , Miller, Kai J. , Baker, Matthew R , Jensen, Michael A , Müller, K. Robert

Mayo Clinic

No container title available | January 22, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.01.20.633934 | PMID 39896506 Get It

Abstract Deep brain stimulation (DBS) is a targeted manipulation of brain circuitry to treat neurological and neuropsychiatric conditions. Optimal DBS lead placement is essential for treatment efficacy. Current targeting practice is based on preoperative and intraoperative brain imaging, intraoperative electrophysiology, and stimulation mapping. Electrophysiological mapping using extracellular microelectrode recordings aids in identifying functional subdomains, anatomical boundaries, and disease-correlated physiology. The shape of single-unit action potentials may differ due to different biophysical properties between cell-types and brain regions. Here, we describe a technique to parameterize the structure and duration of sorted spike units using a novel algorithmic approach based on canonical response parameterization, and illustrate how it may be used on DBS microelectrode recordings. Isolated spike shapes are parameterized then compared using a spike similarity metric and grouped by hierarchical clustering. When spike morphology is associated with anatomy, we find regional clustering in the human globus pallidus. This method is widely applicable for spike removal and single-unit characterization and could be integrated into intraoperative array-based technologies to enhance targeting and clinical outcomes in DBS lead placement. Author summary We developed a new algorithmic approach to capture the structure of single neuron electrophysiology from microelectrode recordings during deep brain stimulation surgery. This method has broad applications for spike characterization, clustering, removal from the background field potential, and comparison across recording sites. Using this technique, we illustrate regional clustering of spike morphologies in the human globus pallidus.
ASRA Pain Medicine consensus practice infection control guidelines for regional anesthesia and pain medicine
Provenzano, David , Hanes, Michael, Hunt, Christine , Benzon, Honorio T. , Grider, Jay S., Cawcutt, Kelly , Doshi, Tina L , Hayek, Salim M. , Hoeltzer, Bryan, Johnson, Rebecca L. , Macfarlane, Alan , Neuman, Stephanie, Pawa, Amit , Pilitsis, Julie G. , Sivanesan, Eellan , Sondekoppam, Rakesh V. , Zundert, Jan Van , Provenzano, David Anthony , Hayek, Salim , Kopp, Sandra , Loftus, Randy W. , Macfarlane, Alan James Robert , Nagpal, Ameet S , Neuman, Stephanie A , Pawa, Amit , Pearson, Amy C S , Sivanesan, Eellan , Sondekoppam, Rakesh V , van Zundert, Jan , Narouze, Samer , Benzon, Honorio T , Cawcutt, Kelly , Johnson, Rebecca L , Doshi, Tina L , Hunt, Christine , Grider, Jay S. , Kalagara, Hari , Kopp, Sandra L. , Nagpal, Ameet , Pearson, Amy C. S. , Narouze, Samer

Mayo Clinic

Regional Anesthesia & Pain Medicine | January 21, 2025 | Volume: No volume available | Issue: No issue available | Pages: rapm-2024-105651

10.1136/rapm-2024-105651 | PMID 39837579 Get It

Background To provide recommendations on risk mitigation, diagnosis and treatment of infectious complications associated with the practice of regional anesthesia, acute and chronic pain management. Methods Following board approval, in 2020 the American Society of Regional Anesthesia and Pain Medicine (ASRA Pain Medicine) commissioned evidence-based guidelines for best practices for infection control. More than 80 research questions were developed and literature searches undertaken by assigned working groups comprising four to five members. Modified US Preventive Services Task Force criteria were used to determine levels of evidence and certainty. Using a modified Delphi method, >50% agreement was needed to accept a recommendation for author review, and >75% agreement for a recommendation to be accepted. The ASRA Pain Medicine Board of Directors reviewed and approved the final guidelines. Results After documenting the incidence and infectious complications associated with regional anesthesia and interventional pain procedures including implanted devices, we made recommendations regarding the role of the anesthesiologist and pain physician in infection control, preoperative patient risk factors and management, sterile technique, equipment use and maintenance, healthcare setting (office, hospital, operating room), surgical technique, postoperative risk reduction, and infection symptoms, diagnosis, and treatment. Consensus recommendations were based on risks associated with different settings and procedures, and keeping in mind each patient’s unique characteristics. Conclusions The recommendations are intended to be multidisciplinary guidelines for clinical care and clinical decision-making in the regional anesthesia and chronic interventional pain practice. The issues addressed are constantly evolving, therefore, consistent updating will be required.
Immunotherapy‐Resistant Neuropathic Pain and Fatigue Predict Quality‐of‐Life in Contactin‐Associated Protein‐Like 2 Antibody Disease
Ceronie, Bryan , Strippel, Christine , Uy, Christopher , Paneva, Sofija , Makuch, Mateusz , Soleimani, Babak , Turaga, Sanchit, Ramanathan, Sudarshini , Michael, Sophia , Varley, James , Easton, Ava , Bennett, David , Irani, Anushka , Irani, Sarosh R. , Ramanathan, Sudarshini , Themistocleous, Andreas , Bennett, David L , Irani, Anushka , Irani, Sarosh R , Paneva, Sofija , Binks, Sophie , Dawes, John M. , Handel, Adam E.

Mayo Clinic

Annals of Neurology | January 18, 2025 | Volume: 97 | Issue: 3 | Pages: 521-528

10.1002/ana.27177 | PMID 39825737 Get It

The long‐term clinical outcomes and associated prognostic factors in contactin‐associated protein‐like 2 (CASPR2)‐antibody diseases are unknown. A total of 75 participants with CASPR2 antibodies were longitudinally assessed for disability, quality‐of‐life, and chronic pain. Although most symptoms improved within 6 months of treatment, neuropathic pain and fatigue were the most immunotherapy refractory, and persisted for up to 6 years. Furthermore, these two factors—but not CASPR2 antibody levels or subclasses—independently predicted worse disability and quality‐of‐life at 24 months. Quality‐of‐life varied widely for any given modified Rankin Scale score, indicating a divergence between patient and clinician assessed outcomes. Further work should study the relative importance of these measures, and the immunopathogenesis underlying intractable symptoms. ANN NEUROL 2025;97:521–528
Amyloid Biomarker Discordance in Patients Evaluated for Anti‐Amyloid Therapy
Graff‐Radford, Jonathan , Lowe, Val J. , Petersen, Ronald C. , Ramanan, Vijay K. , Bornhorst, Joshua , Johnson, Derek R. , Cogswell, Petrice M. , Burkett, Brian J. , Stricker, Nikki H. , Botha, Hugo , Jones, David T. , McCarter, Stuart J. , Neth, Bryan J. , Jack, Clifford R. , Knopman, David S. , Algeciras‐Schimnich, Alicia

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S8 | Pages: No page available

10.1002/alz.095777 Get It

AbstractBackgroundEvidence for abnormal amyloid‐β (Aβ) plaque accumulation is necessary prior to initiating anti‐amyloid therapy in early symptomatic Alzheimer’s disease (AD). While the clinical trials for lecanemab and related drugs utilized positron emission tomography (PET) to demonstrate brain amyloidosis, current appropriate use recommendations for clinical practice consider PET or cerebrospinal fluid (CSF) biomarkers as satisfactory for this purpose. Here, we present four clinical cases where CSF biomarker results were discordant from amyloid PET, with the potential to result in erroneous treatment targeting.MethodPatients were seen at a tertiary care subspecialty clinic in consideration for lecanemab therapy. All patients had office examination, neuropsychological assessment, structural magnetic resonance imaging (MRI), amyloid PET (with either 11C‐Pittsburgh compound B or 18F‐florbetapir), CSF AD biomarkers (Roche Elecsys p‐tau181/Aβ42 and Fujirebio Lumipulse Aβ42/Aβ40 ratios), and apolipoprotein E (APOE) allele testing. Amyloid PET interpretations were made by consensus visual review from experienced readers.ResultAll four patients had clinical diagnoses of mild cognitive impairment or mild dementia (Table 1). Two patients had positive CSF p‐tau181/Aβ42 and Aβ42/40 ratios with negative amyloid PET (indicating sparse to no neuritic plaques). Case 1 displayed aphasia (characterized by anomia and deep dysgraphia) and imaging findings possibly compatible with semantic dementia. Case 2 displayed a gait abnormality and imaging signs of abnormal CSF dynamics. Two other patients had negative CSF p‐tau181/Aβ42 measures with positive amyloid PET (indicating moderate to frequent neuritic plaques). In those instances, the clinical syndrome and imaging studies were strongly supportive of AD and the CSF Aβ42/40 ratio was “likely positive” (Table 1). For one patient (Case 4), tau PET and Lumipulse plasma p‐tau217 concentration were both positive.ConclusionClinicians prescribing anti‐amyloid therapies should be aware of the possibility for CSF biomarkers to be discordant from amyloid PET status in select scenarios. These cases highlight the value of considering PET imaging in the presence of clinically atypical features, concern for mixed etiology, or strong clinical suspicion for AD despite negative CSF biomarkers. Larger series are needed to identify broader patterns contributing to biomarker discordance by assay, modality (PET versus CSF/plasma measures), and medical/neurologic comorbidities.
A Modified Mediterranean Ketogenic Diet reverses signatures and mitigates modifiable risk factors of Alzheimer’s disease
Schweickart, Annalise , Huynh, Kevin, Wang, Tingting , Mellett, Natalie A. , Shi, Pixu , Zemlin, Jasmine , Rahman, Gibraan , Panitchpakdi, Morgan , Meehan, Michael J. , Schimmel, Leyla , Blennow, Kaj, Blach, Colette , Dorrestein, Pieter C. , Krumsiek, Jan , Craft, Suzanne , Huynh, Kevin , Batra, Richa , Neth, Bryan J. , Martino, Cameron , Dilmore, Amanda Hazel , Giles, Corey , Duong, Thy , Shenhav, Liat , Zhang, Anru R. , Karu, Naama , West, Kiana , Weldon, Kelly C. , Register, Thomas C. , Arnold, Matthias , Meikle, Peter J. , Blennow, Kaj , Zetterberg, Henrik , Knight, Rob , Kaddurah‐Daouk, Rima

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S7 | Pages: No page available

10.1002/alz.089878 Get It

AbstractBackgroundAlzheimer’s disease (AD) is a neurodegenerative disorder with significant environmental factors, including diet, that influence its onset and progression. While the ketogenic diet (KD) holds promise in reducing metabolic risks and potentially affecting AD progression, only a few studies have explored the KD’s molecular impact for markers of AD therapeutic potential. The BEAM diet study simultaneously profiled the KD’s effect on the lipidome, blood and cerebrospinal metabolome, and microbiome of both cognitively impaired and cognitively normal individuals. The findings summarized here assess the biological impact of a Modified Mediterranean KD in the context of Alzheimer’s disease treatment and prevention.MethodBEAM involved participants at risk for AD, either cognitively normal or with mild cognitive impairment. The participants consumed both a modified Mediterranean‐ketogenic diet (MMKD) and the American Heart Association diet (AHAD) for 6 weeks each, separated by a 6‐week washout period. We employed HPLC‐MS/MS lipidomics profiling in plasma, nuclear magnetic resonance (NMR)‐based metabolomics to profile serum and CSF, and metagenomics profiling on fecal samples before and after each diet to assess dietary‐induced changes.ResultThe MMKD led to significant alterations in the blood, CSF, and microbiome. These changes included a global elevation across all plasmanyl and plasmenyl ether lipid species, improved modifiable risk factors, like increased HDL‐C and reduced BMI, the reversal of serum metabolic disturbances linked to AD such as an increase in valine levels, and a reduction in systemic inflammation. Leveraging prior clinical studies on AD (n = 1,912), we found that MMKD was inversely associated with the peripheral lipidomic signature of prevalent and incident AD. In the CSF, the MMKD was linked to modified amino acid levels and the breakdown of branched‐chain amino acids (BCAAs). Importantly, we observed a strong correlation between metabolic changes in the CSF and serum, suggesting a systemic regulation of metabolism. In addition, participants with MCI on the MMKD had lower levels of GABA‐producing microbes and GABA, and higher levels of GABA‐regulating microbes.ConclusionOur findings highlight that MMKD can improve AD‐related risk factors, reverse some metabolic disturbances associated with AD, and align metabolic changes across the blood‐CSF barrier.Funding: Alzheimer’s Gut Microbiome Project, NIA U19AG063744
Collaborative large language models for automated data extraction in living systematic reviews
Ayub, Umair , Naqvi, Syed Arsalan Ahmed , Khakwani, Kaneez Zahra Rubab, Sipra, Zaryab bin Riaz, Raina, Ammad, Zhou, Sihan , Saeidi, Amir, Zou, Jia , Leventakos, Konstantinos , Kehl, Kenneth L. , Palmer, Jeanne , Baral, Chitta , He, Huan , Hasan, Bashar , Murad, Mohammad Hassan, Riaz, Irbaz Bin , Khan, Muhammad Ali , He, Huan , Saeidi, Amir, Hasan, Bashar , Rumble, R. Bryan , Bitterman, Danielle S. , Warner, Jeremy L. , Tevaarwerk, Amyé , Murad, M. Hassan

Mayo Clinic

Journal of the American Medical Informatics Association | January 3, 2025 | Volume: 32 | Issue: 4 | Pages: 638-647

10.1093/jamia/ocae325 | PMID 39836495 Get It

Abstract Objective Data extraction from the published literature is the most laborious step in conducting living systematic reviews (LSRs). We aim to build a generalizable, automated data extraction workflow leveraging large language models (LLMs) that mimics the real-world 2-reviewer process. Materials and Methods A dataset of 10 trials (22 publications) from a published LSR was used, focusing on 23 variables related to trial, population, and outcomes data. The dataset was split into prompt development (n = 5) and held-out test sets (n = 17). GPT-4-turbo and Claude-3-Opus were used for data extraction. Responses from the 2 LLMs were considered concordant if they were the same for a given variable. The discordant responses from each LLM were provided to the other LLM for cross-critique. Accuracy, ie, the total number of correct responses divided by the total number of responses, was computed to assess performance. Results In the prompt development set, 110 (96%) responses were concordant, achieving an accuracy of 0.99 against the gold standard. In the test set, 342 (87%) responses were concordant. The accuracy of the concordant responses was 0.94. The accuracy of the discordant responses was 0.41 for GPT-4-turbo and 0.50 for Claude-3-Opus. Of the 49 discordant responses, 25 (51%) became concordant after cross-critique, increasing accuracy to 0.76. Discussion Concordant responses by the LLMs are likely to be accurate. In instances of discordant responses, cross-critique can further increase the accuracy. Conclusion Large language models, when simulated in a collaborative, 2-reviewer workflow, can extract data with reasonable performance, enabling truly “living” systematic reviews.
Antifouling Immunomodulatory Copolymer Architectures That Inhibit the Fibrosis of Implants
Jeang, William J. , Jiang, Alexis L., Bose, Suman , Collins, Evan , McMullen, Patrick , Rosenboom, Jan‐Georg , Lathwal, Sushil , Langer, Robert , Anderson, Daniel G , Wong, Bryan Matthew , Zhao, Yichao , Manan, Rajith S. , Langer, Róbert , Anderson, Daniel G.

Mayo Clinic

Advanced Materials | December 25, 2024 | Volume: 37 | Issue: 7 | Pages: No page available

10.1002/adma.202414743 | PMID 39722171 Get It

Abstract Immune reactions to medical implants often lead to encapsulation by fibrotic tissue and impaired device function. This process is thought to initiate by protein adsorption, which enables immune cells to attach and mount an inflammatory response. Previously, several antifibrotic materials have been either designed to reduce protein adsorption or discovered via high‐throughput screens (HTS) to favorably regulate inflammation. The present work introduces antifouling immunomodulatory (AIM) copolymer coatings, which combine both strategies to effectively enhance implant protection. AIM copolymers synergistically integrate zwitterionic moieties to resist protein fouling, HTS‐derived antifibrotics for immunomodulation, and silane monomers for grafting to diverse substrates including elastomers, ceramics, and metals. Interestingly, simply combining these monomers into conventional random or block copolymer architectures yielded no significant advantage over homopolymers. By contrast, an unusual polymer chain architecture — a zwitterionic block flanked by a mixed zwitterionic immunomodulatory segment — showed superior fibrosis resistance in both peritoneal and subcutaneous sites over one month in immunocompetent mice. This architecture also improved the performance of two different HTS‐derived antifibrotic monomers, suggesting that tailoring AIM architectures may broadly complement immunomodulatory chemistries and provide a versatile approach to improving implant longevity.
Changes in breast cancer risk associated with benign breast disease from 1967 to 2013
Degnim, Amy C. , Ghosh, Karthik , Vierkant, Robert A. , Winham, Stacey J. , Hoskin, Tanya L. , Carter, Jodi M. , McCauley, Bryan M. , Jensen, Matt R., Allers, Teresa, Frost, Marlene H., Gehling, Denice, Fischer, Jessica, Seymour, Lisa R. , Denison, Lori A., Vachon, Celine M. , Hartmann, Lynn C. , Frost, Marlene, Gehling, Denice L, Fischer, Jessica L, Pacheco-Spann, Laura M , Rosenberg, Philip S , Vachon, Celine M. , Radisky, Derek C , Sherman, Mark E , Winham, Stacey J , Degnim, Amy C , Vierkant, Robert A , Hoskin, Tanya , Carter, Jodi , Pacheco-Spann, Laura M. , Rosenberg, Philip S. , Radisky, Derek C. , Sherman, Mark E.

Mayo Clinic

JNCI Cancer Spectrum | December 23, 2024 | Volume: 9 | Issue: 1 | Pages: No page available

10.1093/jncics/pkae128 | PMID 39786446 Get It

Abstract Background Benign breast disease (BBD) increases breast cancer (BC) risk progressively for women diagnosed with nonproliferative change, proliferative disease without atypia (PDWA), and atypical hyperplasia (AH). Leveraging data from 18 704 women in the Mayo BBD Cohort (1967-2013), we evaluated temporal trends in BBD diagnoses and how they have influenced associated BC risk over 4 decades. Methods BC risk trends associated with BBD were evaluated using standardized incidence ratios (SIRs) and age–period–cohort modeling across 4 eras—premammogram (1967-1981), precore needle biopsy (CNB) (1982-1992), transition to CNB (1993-2001), and CNB era (2002-2013). Results With a median follow-up of 15.8 years, 9.9% of women were diagnosed with BC (invasive and/or DCIS). From the premammogram era to the CNB era, we observed a significant increase in BC risk, rising from an SIR of 1.61 to 1.99. The proportion of proliferative BBD diagnoses (PDWA or AH) increased markedly over time (28.1%-49.7%), as did the proportion of DCIS events (11%-28%; χ2 P &lt; .001). Within specific BBD categories, the risk of invasive BC increased modestly. Conclusions Absolute risk of BC within BBD categories remained stable, but the relative risk of BC after BBD increased over time due to notable increases in higher risk BBD lesions, specifically PDWA and AH. These findings illustrate how evolving screening practices have changed the risk profile of BBD and should inform management strategies for patients with BBD in modern clinical settings.